Amneal Pharmaceuticals (AMRX) Capital Expenditures (2017 - 2026)

Amneal Pharmaceuticals' Capital Expenditures history runs 10 years deep, the most recent figure standing at $8.2 million for Q1 2026.

• On a quarterly basis, Capital Expenditures fell 37.89% year-over-year to $8.2 million in Q1 2026; TTM through Mar 2026 was $65.1 million, a 16.44% increase from a year earlier, with the FY2025 full-year figure at $70.1 million, up 34.93% from the prior year.
• Capital Expenditures declined to $8.2 million in Q1 2026 per AMRX's latest filing, from $21.8 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $22.8 million in Q2 2025 and bottomed at $5.0 million in Q2 2022.
• The 5-year median for Capital Expenditures is $11.7 million (2023), against an average of $12.9 million.
• Biggest YoY gain for Capital Expenditures was 137.73% in 2023; the steepest drop was 38.95% in 2023.
• Year by year, Capital Expenditures stood at $11.5 million in 2022, then declined by 13.96% to $9.9 million in 2023, then jumped by 53.62% to $15.2 million in 2024, then surged by 43.67% to $21.8 million in 2025, then sank by 62.45% to $8.2 million in 2026.
• Per Business Quant, the three latest AMRX Capital Expenditures figures stand at $8.2 million (Q1 2026), $21.8 million (Q4 2025), and $12.3 million (Q3 2025).